A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy

Trial Profile

A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Birinapant (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top